Suraj Muley, MD, FAAN, FRCP, FACP

Dr. Muley highlights patient-reported experience from MINT: the once-every-six-month maintenance regimen (after initial loading doses) was well-received, giving patients extended windows free from treatment considerations.

Dr. Muley frames two use cases: (1) Early use (<1 year disease duration) to intercept long-lived plasma cell formation and potentially reduce steroid/immunosuppressant reliance; (2) Later use in patients who have failed steroids, conventional ISTs, or downstream therapies (FcRn inhibitors, complement inhibitors).

Dr. Muley addresses long-term safety of sustained B cell depletion, drawing a parallel to decades of use in MS.

Dr. Muley synthesizes the data: durable response at 52 weeks in both AChR+ and MuSK+ patients with no new safety signals.

Dr. Muley explains the rationale for examining disease duration: concern that longer disease may reduce reversibility due to structural muscle membrane changes, plus European data suggesting early B cell depletion may alter long-term disease course.

Dr. Muley distinguishes the two antibody subtypes: MuSK autoantibodies are IgG4 (no complement activation); AChR antibodies are IgG1/IgG3 (complement-activating).

Dr. Muley covers the MuSK-positive subgroup: 48 patients randomized, 46 entered the OLP, 44 completed 26 weeks.

Dr. Muley reviews the MINT open-label period 1-year interim data.

Dr. Muley outlines the immunopathogenesis of generalized myasthenia gravis, tracing the cascade from thymic dysregulation through autoreactive T cells, B cell activation, and plasmablast/plasma cell formation to autoantibody production against AChR and MuSK.

Experts weigh CIDP care: IVIG limits, emerging therapies, early-yet-accurate diagnosis, objective response checks, and screening for paraproteins.

Clinicians explain long-term CIDP care: set expectations for ongoing therapy, taper safely, reassess often, and add rehab, mental health, nutrition.

Learn how clinicians partner with CIDP patients to choose IVIG, steroids or SCIG, set expectations, and tailor treatment to real life.

Learn how clinicians set CIDP treatment goals: gradual strength gains, managing residual deficits, IVIG tapering, and defining remission.

Objective CID

FcRn inhibitors emerge for CIDP relapse prevention, yet biomarker gaps and careful transitions from IVIG shape who benefits.

Explore subcutaneous immunoglobulin for CIDP: HYQVIA and HYZENTRA data, who benefits most, and how it compares with IVIG side effects.

Experts discuss tailoring IVIG for CIDP—optimizing dose and intervals, monitoring relapse risk, and overcoming access and tolerability barriers.

Real-world CIDP data show IVIG slows disability progression and may ease pain, with insights on study limits and patient outcomes.

Explore evidence-based CIDP therapy: IVIG dosing from the ICE trial, steroid tradeoffs, and how clinicians tailor treatment to comorbidities.

CIDP management tackles fatigue, pain, mood, and rehab—plus the hunt for early biomarkers and more effective therapies.

In this episode, "Navigating CIDP Guidelines, Misdiagnosis, and Disease Variants," the panelists in neurology and neuromuscular medicine explore the practical utility of the 2021 EAN/PNS CIDP guidelines and the considerable complexity introduced by disease variants. The discussion opens with a question about monophasic CIDP, with one expert noting that 20–30% of patients can achieve drug-free remission after initial treatment, suggesting a subset of patients experience a self-limiting course that nonetheless meets the diagnostic threshold of progression or relapse beyond two months.

Welcome back to another NeurologyLive Peer Exchange series. The panel opens with a discussion of CIDP prevalence, noting that estimates vary depending on the diagnostic criteria used. A strict case definition from a New South Wales population study places prevalence at approximately 1 per 100,000, while a more clinically based study from Olmsted County suggests a higher figure of around 1 in 10,000. One expert contextualizes this further, estimating that roughly 40,000–50,000 patients in the U.S. are affected, and that CIDP accounts for approximately 20% of patients presenting to peripheral neuropathy centers with initially unrecognized neuropathy. The panel characterizes CIDP as rare but not ultra-rare.